Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) announced a partnership with a leading nutraceutical manufacturer for the initial production of its VITA-SHIELD-MAX Immune Booster. This proprietary formulation aims to enhance natural immunity, developed after extensive research and consultations with medical professionals. CEO William A. Hartman expressed confidence that the product, supported by third-party research materials, will appeal to large retailers. The company maintains exclusive rights to numerous COVID-19 treatment technologies, emphasizing its compliance with OTC reporting requirements.

Positive

• Secured contract with a major nutraceutical manufacturer for VITA-SHIELD-MAX production.
• Formulation designed to significantly boost immune health based on extensive research.
• Accompanied by third-party medical articles to support its sales strategy.
• Holds exclusive rights to various COVID-19 treatment technology patents.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / March 16, 2021 / Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberd's VITA-SHIELD-MAX^TM Immune Booster. Halberd's scientists designed this proprietary combination of vitamins and minerals to help the body increase its natural immunity and promote general health.

Dr. Patricio Reyes, Halberd Corporation's Chief Technical Officer, indicated, "Halberd's formulation was not arrived at lightly. After much research and discussions with medical professionals here and abroad, this combination of ingredients was selected to provide significant immune boosting capability."

William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, "This initial production will be used along with a booklet of third party medical articles supporting our selection of ingredients to aid our sales associates in presenting our product to potential big volume retailers and customers. We are confident that they will find that our formulation meets or exceeds their expectations."

To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus," and "Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/635655/Halberd-Corporation-Starts-VITA-SHIELD-MAXTM-Immunity-Boosting-Nutraceutical-Production

FAQ

What is Halberd Corporation's latest product announcement?

Halberd Corporation announced a contract for the production of its VITA-SHIELD-MAX Immune Booster.

What is VITA-SHIELD-MAX?

VITA-SHIELD-MAX is an immune booster formulated with vitamins and minerals to enhance natural immunity.

Who is producing VITA-SHIELD-MAX for Halberd Corporation?

Halberd Corporation has contracted with a major nutraceutical manufacturer for the production.

What patents does Halberd Corporation hold related to COVID-19?

Halberd holds exclusive rights to several COVID-19 treatment technology patents, enhancing its market position.

When was the contract for VITA-SHIELD-MAX announced?

The contract was announced on March 16, 2021.